Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 6/2021

01-06-2021 | SARS-CoV-2 | Original Article

Clinical characteristics of re-hospitalized COVID-19 patients with recurrent positive SARS-CoV-2 RNA: a retrospective study

Authors: Lei Pan, Runsheng Wang, Na Yu, Chao Hu, Junhong Yan, Xiaomin Zhang, Tao Wang, Jungui Hao, Fuquan Gao, Tonggang Liu, Jing Wang, Xiaojing Liu, Mi Mu, Wei Huang, Yongzhong Guo, Changjun Lv, Xiaozhi Wang, Lei Tu, Kun Wan, Guogang Xu

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 6/2021

Login to get access

Abstract

At present, it has been noticed that some patients recovered from COVID-19 present a recurrent positive RNA test of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) after being discharged from hospitals. The purpose of the current study was to characterize the clinical features of re-hospitalized patients with recurrent SARS-CoV-2 positive results. From January 12 to April 1 of 2020, our retrospective study was conducted in China. The exposure history, baseline data, laboratory findings, therapeutic schedule, and clinical endpoints of the patients were collected. All the patients were followed until April 10, 2020. Among all COVID-19 patients included in the current study, there were 14 re-hospitalized patients due to recurrent positive tests of SARS-CoV-2 RNA. Fever (11 [78.6%]), cough (10 [71.4%]), and fatigue (7 [50.0%]) were the most common symptoms on the patient’s first admission, and less symptoms were found on their second admission. The average duration from the onset of symptoms to admission to hospital was found to be 8.4 days for the first admission and 2.6 days for the second admission (P = 0.002). The average time from the detection of RNA (+) to hospitalization was 1.9 days for the first admission and 2.6 days for the second admission (P = 0.479), and the average time from RNA (+) to RNA (−) was 11.1 days for the first admission and 6.3 days for the second admission (P = 0.030). Moreover, the total time in hospital was 18.6 days for the first admission and 8.0 days for the second admission (P = 0.000). It may be necessary to increase the isolation observation time and RT-PCR tests should be timely performed on multiple samples as soon as possible.
Literature
2.
8.
go back to reference Khot WY, Nadkar MY (2020) The 2019 novel coronavirus outbreak - a global threat. J Assoc Physicians India 68:67–71PubMed Khot WY, Nadkar MY (2020) The 2019 novel coronavirus outbreak - a global threat. J Assoc Physicians India 68:67–71PubMed
Metadata
Title
Clinical characteristics of re-hospitalized COVID-19 patients with recurrent positive SARS-CoV-2 RNA: a retrospective study
Authors
Lei Pan
Runsheng Wang
Na Yu
Chao Hu
Junhong Yan
Xiaomin Zhang
Tao Wang
Jungui Hao
Fuquan Gao
Tonggang Liu
Jing Wang
Xiaojing Liu
Mi Mu
Wei Huang
Yongzhong Guo
Changjun Lv
Xiaozhi Wang
Lei Tu
Kun Wan
Guogang Xu
Publication date
01-06-2021
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 6/2021
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-020-04151-9

Other articles of this Issue 6/2021

European Journal of Clinical Microbiology & Infectious Diseases 6/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.